# Arabinoxylan Rice Bran (MGN-3/Biobran) for the Treatment of Hepatocellular Carcinoma and Hepatitis B and C Infection

> **NCT01018381** · NA · COMPLETED · sponsor: **The 108 Military Central Hospital** · enrollment: 130 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Hepatitis B

## Interventions

- **PROCEDURE:** PEIT
- **PROCEDURE:** TOCE
- **PROCEDURE:** TOCE plus PEIT
- **PROCEDURE:** TOCE plus RFA
- **DIETARY_SUPPLEMENT:** MGN-3
- **DRUG:** Entecavir

## Key facts

- **NCT ID:** NCT01018381
- **Lead sponsor:** The 108 Military Central Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2008-07
- **Final completion:** 2009-11
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2009-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01018381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01018381, "Arabinoxylan Rice Bran (MGN-3/Biobran) for the Treatment of Hepatocellular Carcinoma and Hepatitis B and C Infection". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01018381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*